<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006468</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068282</org_study_id>
    <secondary_id>FRE-GERCOR-OPTIMOX-2000</secondary_id>
    <secondary_id>EU-20034</secondary_id>
    <nct_id>NCT00006468</nct_id>
  </id_info>
  <brief_title>Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Phase III Study of An Optimized LV-5FU-Oxaliplatin Regimen in Metastatic Colorectal Cancer. C99-1.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which regimen of combination chemotherapy is more effective for metastatic&#xD;
      colorectal cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two combination&#xD;
      chemotherapy regimens in treating patients who have metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of intermittent high-dose oxaliplatin in combination with a&#xD;
           simplified bimonthly regimen of leucovorin calcium (LV) and fluorouracil (5-FU) vs&#xD;
           standard dose oxaliplatin in combination with the standard bimonthly regimen of LV and&#xD;
           5-FU in patients with metastatic colorectal cancer.&#xD;
&#xD;
        -  Determine the time to treatment failure, tolerance, response rate, and overall survival&#xD;
           in patients treated with these 2 regimens.&#xD;
&#xD;
        -  Compare quality of life of these patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to treatment center, performance status (0-1 vs 2), and number of metastatic sites&#xD;
      (1 vs more than 1). Patients are randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oxaliplatin IV over 2 hours on day 1, and leucovorin calcium IV&#xD;
           over 2 hours followed by fluorouracil (5-FU) IV over 22 hours on days 1 and 2.&#xD;
&#xD;
        -  Arm II: Patients receive oxaliplatin IV and leucovorin calcium IV over 2 hours followed&#xD;
           by 5-FU IV over 46 hours beginning on day 1 for courses 1-6 and 19-24. For courses 7-18,&#xD;
           patients receive leucovorin calcium IV followed by 5-FU IV as above beginning on day 1.&#xD;
&#xD;
      Courses repeat every 14 days in both arms in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, after courses 4 and 6, and every 6 courses&#xD;
      thereafter.&#xD;
&#xD;
      Patients are followed monthly for 3 months and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 460 patients (230 per treatment arm) will be accrued for this&#xD;
      study within 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2000</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed unresectable metastatic adenocarcinoma of the colon or rectum&#xD;
&#xD;
          -  Bidimensionally measurable or evaluable disease outside previously irradiated area&#xD;
&#xD;
               -  No bone metastasis as target lesion&#xD;
&#xD;
               -  At least 1 cm if spiral CT scan OR&#xD;
&#xD;
               -  At least 2 cm if conventional CT scan&#xD;
&#xD;
          -  No CNS metastasis&#xD;
&#xD;
          -  No symptomatic ascites or pleural effusion that is not evacuated&#xD;
&#xD;
          -  No total or partial bowel obstruction&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Alkaline phosphatase less than 5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 3 times ULN&#xD;
&#xD;
          -  No uncontrolled hypercalcemia&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled congestive heart failure, angina pectoris, hypertension, or&#xD;
             arrhythmias&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No peripheral sensory neuropathy&#xD;
&#xD;
          -  No prior significant neurologic or psychiatric disorders&#xD;
&#xD;
          -  No other malignancy within past 5 years except adequately treated carcinoma in situ of&#xD;
             the cervix or basal or squamous cell skin carcinoma&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other concurrent serious disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior immunotherapy for metastatic disease&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed, provided progression-free interval of more than 6&#xD;
             months since end of last course&#xD;
&#xD;
          -  No prior oxaliplatin or irinotecan&#xD;
&#xD;
          -  No prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Concurrent surgery allowed&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 30 days since other prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational treatment&#xD;
&#xD;
          -  No other concurrent antitumoral treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aimery de Gramont, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Saint Antoine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2000</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 10, 2009</last_update_submitted>
  <last_update_submitted_qc>January 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2009</last_update_posted>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

